NIAID VRC NUCLEIC ACID AND LIPID TECHNOLOGY DEVELOPMENT

NIAID的任务和范围包括通过研究、开发和临床测试新发和地方性传染病的疫苗和疗法来快速应对传染病暴发。2019年，为了应对新冠肺炎疫情的爆发，基因疫苗被迅速开发出来并进行了临床评估，导致两种用于预防19型冠状病毒的疫苗最终获得了美国食品和药物管理局的许可。快速反应的部分内容包括快速制造核酸，以支持试剂和疫苗的制造和测试，这种疫苗可用于多种传染病，如艾滋病毒、冠状病毒、流感、呼吸道合胞病毒等。 此外，开发的LNP制剂将支持多种传染病(包括但不限于艾滋病毒、冠状病毒、流感)的mRNA-LNP包裹疫苗，获得临床可用的脂质纳米颗粒(LNP)制剂将使人类安全使用的疫苗配方的低风险加速。

The NIAID mission and scope includes rapidly responding to infectious disease outbreaks through research, development, and clinical testing of vaccines and therapeutics for emerging and endemic infectious diseases. In 2019, in response to the COVID-19 outbreak, mRNA vaccines were quickly developed and evaluated clinically, leading to the eventual FDA-licensure of 2 vaccines used in the prevention of COVID 19. Part of that quick response included rapid manufacturing of nucleic acid (DNA and RNA) to support reagent and vaccine manufacturing and testing, which would be amendable for multiple infectious diseases such as HIV, CoV, Influenza, RSV, among other diseases. Additionally, the LNP formulations developed would support mRNA-LNP encapsulated vaccines for multiple infectious diseases, including but not limited to HIV, CoV, Influenza, and access to clinically available lipid nanoparticle (LNP) formulations would enable low risk acceleration of vaccine formulations safe for human use.